ARIES 144 Week Results: Durable Virologic Suppression in HIV-Infected Patients Simplified to Unboosted Atazanavir/Abacavir/Lamivudine

REFERENCES

• Panel on Antiretroviral Guidelines for Adults and Ado-lescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. US Depart-ment of Health and Human Services. October 14,2011; 1–167. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed October 27,2011.
   Google Scholar
• Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treat-ment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA Panel. JAMA. 2010; 304:321–333.
   PubMed Web of Science ®Google Scholar
• European AIDS Clinical Society Guidelines. Version 6.0. October 2011; 1–156. www.europeanaidsclinicalsociety.org. Accessed on October 27,2011.
   Google Scholar
• Carr A. Toxicity of antiretroviral therapy and implications for drug development. Nat Rev Drug Discov. 2003;2:624–634.
   PubMed Web of Science ®Google Scholar
• Becker S. The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral ther-apy. Expert Opin Investig Drugs. 2003;12(3):410–412.
   Web of Science ®Google Scholar
• Gatti G, Di Biagio A, Casazza R, et al. The relation-ship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. AIDS. 1999;13:2083–2089.
   PubMed Web of Science ®Google Scholar
• Samaras K, Richardson R, Carr A. Postprandial lipid effects of low-dose ritonavir vs. raltegravir in HIV-uninfected adults. AIDS. 2010; 24:1727–1731.
   PubMed Web of Science ®Google Scholar
• Collot-Teixeira S, De Lorenzo F, et al. Impact of different low-dose ritonavir regimens on lipids, CD36, and adipophilin expression. Clin Pharmacol Ther 2009;85(4):375–378.
   PubMed Web of Science ®Google Scholar
• Yilmaz S, Boffito M, Collot-Teixeira S, et al. Investiga-tion of low-dose ritonavir on human peripheral blood mononuclear cells using gene expression whole genome microarrays. Genomics. 2010;96(1):57–65.
   PubMed Web of Science ®Google Scholar
• Squires KE, Young B, DeJesus E; ARIES Study Team. Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients. HIV Clin Trials. 2010;11(2):69–79.
   PubMed Web of Science ®Google Scholar
• Squires KE, Young B, Dejesus E; ARIES Study Team. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. AIDS. 2010;24(13):2019–2027.
   PubMed Web of Science ®Google Scholar
• HIV Drug Resistance Mutations. http://www.iasusa.org/resistance_mutations/index.html. December 2010. Accessed September 20, 2011
   Google Scholar
• Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomeru-lar filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–470.
   PubMed Web of Science ®Google Scholar
• Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treat-ment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497. http://www.nhIbi.nih.gov/guidelines/cholesterol/atp3xsum.pdf.
   PubMed Web of Science ®Google Scholar
• Pavie J, Porcher R, Torti C, et al. Efficacy and safety of a switch to unboosted atazanavir in combination with nucle-oside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy. J Antimicrob Chemother 2011; 66:2372–2378.
   PubMed Web of Science ®Google Scholar
• Ghosn J, Carosi G, Moreno S, et al. Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen. Antivir Ther 2010;15(7):993–1002.
   PubMed Web of Science ®Google Scholar
• Fux CA, Rauch A, Simcock M, et al; Swiss HIV Cohort Study. Tenofovir use is associated with a reduction in cal-culated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther 2007;12:1165–1173.
   PubMed Web of Science ®Google Scholar
• Albini L, Cesana BM, Motta D, et al. A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naïve HIV-infected patients after tenofovir/ emtricitabine in combination with atazanavir/ritonavir or efavirenz. J Acquir Immune Defic Syndr 2012 59(1):18–30.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Kirk O, Reiss P, et al; EuroSIDA Study Group. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS. 2010;24(11):1667–1678.
   PubMed Web of Science ®Google Scholar
• Sax PE, Tierney C, Collier AC, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis. 2011; 204:1191–1201.
   PubMed Web of Science ®Google Scholar
• Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopi-navir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372:646–655.
   PubMed Web of Science ®Google Scholar
• Elion R, DeJesus E, Sension M, et al. Once-daily aba-cavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48 week pilot study. HIV Clin Trials. 2008:9(3):152–163.
   PubMed Web of Science ®Google Scholar
• Truvada (Gilead BioSciences) label approved July 8, 2011. http://www.accessdata.fda.gov/drugsatfda_docs/labe1/2011/021752s027Ib1.pdf. Accessed June 12,2012.
   Google Scholar